Presentation is loading. Please wait.

Presentation is loading. Please wait.

Less Drugs for more Safety, Convenience and Sustainability: the Italian experiences Roma, Istituto Superiore Sanità 10-11 marzo 2011 Switch e strategie.

Published byThomas Cook Modified over 10 years ago

Similar presentations

Presentation on theme: "Less Drugs for more Safety, Convenience and Sustainability: the Italian experiences Roma, Istituto Superiore Sanità 10-11 marzo 2011 Switch e strategie."— Presentation transcript:

1 Less Drugs for more Safety, Convenience and Sustainability: the Italian experiences Roma, Istituto Superiore Sanità 10-11 marzo 2011 Switch e strategie di mantenimento: i nuovi paradigmi nellesperienza Silvia Nozza italiana

2 Randomized, multicenter, comparative open-labeled study. Proof-of-concept. 60 HIV-infected Treatment-Naive Subjects. AIM OF THE STUDY To evaluate virologic efficacy of Maraviroc associated to Kaletra in HIV-Infected Treatment-Naive Subjects. Studio VEMAN

3 Elegible subjects Trofile R5 Randomization 1:1 Truvada + Kaletra Maraviroc 150 mg QD Kaletra

4 Virological results p=0.056 19 pts in MVC-KAL 19 pts in TDF/FTC-kAL

5 Immunological results p=0.056

6 Only pts infected with R5 virus. Low flexibility; could be a switch regimen? Flexibility

7 3/41 (7%) pts stopped therapy at W12 due to diarrhea No significant increase in AST, ALT, CPK, cholesterol, tryglicerides and glycaemia in both groups. Safety

8 At week 48 100% pts with undetectable viral load. 20 pts (10 in group MVC and 10 in group TDF/FTC) reached W96; they are still undetectable Durability

Download ppt "Less Drugs for more Safety, Convenience and Sustainability: the Italian experiences Roma, Istituto Superiore Sanità 10-11 marzo 2011 Switch e strategie."

Similar presentations

Single Pill HIV Regimens – Introducing the Quad Pedro Cahn, MD Jean-Pierre Routy, MD Calvin Cohen, MD.

Single Pill HIV Regimens – Introducing the Quad Pedro Cahn, MD Jean-Pierre Routy, MD Calvin Cohen, MD.
Switch to LPV/r monotherapy - Pilot LPV/r - M03-613 - American Study - KalMo - OK - OK04 - KALESOLO - MOST - HIV-NAT 077.

Switch to LPV/r monotherapy - Pilot LPV/r - M American Study - KalMo - OK - OK04 - KALESOLO - MOST - HIV-NAT 077.
Switch EFV to ETR - Efavirenz to Etravirine. Efavirenz to Etravirine switch in patients with CNS adverse events Waters L, AIDS 2011;25:65-71 Design Endpoints.

Switch EFV to ETR - Efavirenz to Etravirine. Efavirenz to Etravirine switch in patients with CNS adverse events Waters L, AIDS 2011;25:65-71 Design Endpoints.
Innovative Strategies for the Management of HIV Infection Dual therapies without NRTIs Jean-Guy Baril, MD Clinique médicale du Quartier Latin CHUM This.

Innovative Strategies for the Management of HIV Infection Dual therapies without NRTIs Jean-Guy Baril, MD Clinique médicale du Quartier Latin CHUM This.
ARV overview and toxicity Dr Francois Venter Reproductive Health Research Unit University of the Witwatersrand.

ARV overview and toxicity Dr Francois Venter Reproductive Health Research Unit University of the Witwatersrand.
A5336 A Phase IIa, Double-blind, Placebo-controlled, Randomized Trial of Ruxolitinib in Antiretroviral-treated HIV-Infected Adults CAB Draft Discussion.

A5336 A Phase IIa, Double-blind, Placebo-controlled, Randomized Trial of Ruxolitinib in Antiretroviral-treated HIV-Infected Adults CAB Draft Discussion.
Hepatitis web study Hepatitis web study Peginterferon alfa-2a + RBV versus Interferon alfa-2a + RBV ACTG 5071 Phase 2 Treatment Naïve, Chronic HCV and.

Hepatitis web study Hepatitis web study Peginterferon alfa-2a + RBV versus Interferon alfa-2a + RBV ACTG 5071 Phase 2 Treatment Naïve, Chronic HCV and.
Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:1207-17.

Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:
Comparison of RTV vs Cobi  GS-US-216-0114. Gallant JE. JID 2013;208:32-9 GS-US-216-0114  Design  Objective –Non inferiority of COBI compared with RTV.

Comparison of RTV vs Cobi  GS-US Gallant JE. JID 2013;208:32-9 GS-US  Design  Objective –Non inferiority of COBI compared with RTV.
Hepatitis web study Hepatitis web study Telaprevir BID versus q8 in Treatment Naïve GT-1 OPTIMIZE (Study C211) Phase 3 Treatment Naïve Buti M, et al. Gastroenterology.

Hepatitis web study Hepatitis web study Telaprevir BID versus q8 in Treatment Naïve GT-1 OPTIMIZE (Study C211) Phase 3 Treatment Naïve Buti M, et al. Gastroenterology.
Switch to RAL-containing regimen  Canadian Study  CHEER  Montreal Study  EASIER  SWITCHMRK  SPIRAL  Switch ER.

Switch to RAL-containing regimen  Canadian Study  CHEER  Montreal Study  EASIER  SWITCHMRK  SPIRAL  Switch ER.
Simplification from Protease Inhibitors to Once or Twice Daily Raltegravir: the ODIS trial Eugenia Vispo, Pablo Barreiro, Francisco Blanco, Sonia Rodríguez-Novoa*,

Simplification from Protease Inhibitors to Once or Twice Daily Raltegravir: the ODIS trial Eugenia Vispo, Pablo Barreiro, Francisco Blanco, Sonia Rodríguez-Novoa*,
Efficacy and Safety of Maraviroc in Treatment- Experienced (TE) Patients Infected with R5 HIV-1: 96-week Combined Analysis of the MOTIVATE 1 & 2 Studies.

Efficacy and Safety of Maraviroc in Treatment- Experienced (TE) Patients Infected with R5 HIV-1: 96-week Combined Analysis of the MOTIVATE 1 & 2 Studies.
Switch to ATV- or ATV/r-containing regimen Switch to ATV/r-containing regimen  ATAZIP Switch to ATV ± r-containing regimen  SWAN Study  SLOAT Study.

Switch to ATV- or ATV/r-containing regimen Switch to ATV/r-containing regimen  ATAZIP Switch to ATV ± r-containing regimen  SWAN Study  SLOAT Study.
Comparison of EFV vs MVC  MERIT Study.  Design N = 361 N = 360  Objective –Non inferiority of MVC vs EFV: % HIV RNA < 400 c/mL and < 50 c/mL (co-primary.

Comparison of EFV vs MVC  MERIT Study.  Design N = 361 N = 360  Objective –Non inferiority of MVC vs EFV: % HIV RNA < 400 c/mL and < 50 c/mL (co-primary.
Comparison of PI vs PI  ATV vs ATV/r BMS 089  LPV/r mono vs LPV/r + ZDV/3TCMONARK  LPV/r QD vs BIDM02-418 M05-730 A5073  LPV/r + 3TC vs LPV/r + 2 NRTIGARDEL.

Comparison of PI vs PI  ATV vs ATV/r BMS 089  LPV/r mono vs LPV/r + ZDV/3TCMONARK  LPV/r QD vs BIDM M A5073  LPV/r + 3TC vs LPV/r + 2 NRTIGARDEL.
SAILING Efficacy and safety of dolutegravir (DTG) in treatment- experienced INI-naïve patients DK/DLG/0041/14c September 2015.

SAILING Efficacy and safety of dolutegravir (DTG) in treatment- experienced INI-naïve patients DK/DLG/0041/14c September 2015.
NRTI-sparing  SPARTAN  PROGRESS  NEAT001/ANRS 143  MODERN.

NRTI-sparing  SPARTAN  PROGRESS  NEAT001/ANRS 143  MODERN.
POWER 3 Study Confirms Safety and Efficacy of Darunavir/Ritonavir in Treatment-Experienced Patients Slideset on: Molina JM, Cohen C, Katlama C, et al.

POWER 3 Study Confirms Safety and Efficacy of Darunavir/Ritonavir in Treatment-Experienced Patients Slideset on: Molina JM, Cohen C, Katlama C, et al.
Slideset on: Gathe J, da Silva BA, Cohen DE, et al. A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in.

Slideset on: Gathe J, da Silva BA, Cohen DE, et al. A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in.

Similar presentations

Ads by Google